Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET

Company Participants

Peter Vozzo - ICR Westwicke, Investor Relations
Jack Khattar - Chief Executive Officer
Tim Dec - Chief Financial Officer

Conference Call Participants

Andrew Tsai - Jefferies
David Amsellem - Piper Sandler
Stacy Ku - TD Cowen
Annabel Samimy - Stifel

Operator

Good afternoon, and welcome to the Supernus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Peter Vozzo of ICR Westwicke, Investor Relations representative for Supernus Pharmaceutical. You may now begin.

Peter Vozzo

Thank you, Karin. Good afternoon, everyone, and thank you for joining us today for Supernus Pharmaceuticals' second quarter 2024 financial results conference call. Today, after the close of the market, the company issued a press release announcing these results.

On the call with me today are Supernus' Chief Executive Officer, Jack Khattar; and Chief Financial Officer, Tim Dec. Today's call is being made available via the Investor Relations section of the company's website at ir.supernus.com.

During the course of this call, the management may make certain forward-looking statements regarding future events and the company's future performance. These forward-looking statements reflect Supernus' current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the Risk Factors section of the company's latest SEC filings. Actual results may differ materially from those projected in these forward-looking statements.

For the benefit of those of you who may be listening to the replay, this call is being held and recorded on August 6, 2024. Since then, the company may have made additional announcements related to the topics discussed. Please reference the company's most recent press releases and current filings with the SEC. Supernus declines any obligation to update these forward-looking statements, except as required by applicable securities laws.

I'll now turn the call over to Jack.

Jack Khattar

Thank you, Peter. Good afternoon, everyone, and thanks for taking the time to join us on today's call. In the second quarter of 2024, we delivered strong net sales growth from our key growth drivers, Qelbree and GOCOVRI and continue to advance our product pipeline, including SPN-817 for treatment-resistant seizures and SPN-820 or depression.